Daxor Corporation
Daxor Corporation (DXR) Stock Competitors & Peer Comparison
See (DXR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DXR | $10.95 | +1.86% | 54.5M | 6.59 | $1.64 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.47% |
| BDX | $142.35 | -0.78% | 51.6B | 24.88 | $5.72 | +2.47% |
| ALC | $65.97 | +3.66% | 32.1B | 39.49 | $1.67 | +0.54% |
| MDLN | $36.02 | -0.47% | 30.5B | 31.60 | $1.14 | N/A |
| WST | $304.41 | +0.50% | 21.5B | 40.71 | $7.48 | +0.29% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.47% |
| COO | $60.94 | +2.23% | 11.9B | 30.32 | $2.01 | N/A |
| BAX | $17.79 | +2.83% | 9.2B | -9.32 | -$1.91 | +2.03% |
Stock Comparison
DXR vs BDXA Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, DXR is priced at $10.95, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas BDXA's P/E ratio is 21.44. In terms of profitability, DXR's ROE is +0.22%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, DXR is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check BDXA's competition here
DXR vs BDX Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, BDX has a market cap of 51.6B. Regarding current trading prices, DXR is priced at $10.95, while BDX trades at $142.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas BDX's P/E ratio is 24.88. In terms of profitability, DXR's ROE is +0.22%, compared to BDX's ROE of +0.05%. Regarding short-term risk, DXR is less volatile compared to BDX. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check BDX's competition here
DXR vs ALC Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, ALC has a market cap of 32.1B. Regarding current trading prices, DXR is priced at $10.95, while ALC trades at $65.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas ALC's P/E ratio is 39.49. In terms of profitability, DXR's ROE is +0.22%, compared to ALC's ROE of +0.04%. Regarding short-term risk, DXR is less volatile compared to ALC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ALC's competition here
DXR vs MDLN Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, MDLN has a market cap of 30.5B. Regarding current trading prices, DXR is priced at $10.95, while MDLN trades at $36.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas MDLN's P/E ratio is 31.60. In terms of profitability, DXR's ROE is +0.22%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, DXR is less volatile compared to MDLN. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check MDLN's competition here
DXR vs WST Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, WST has a market cap of 21.5B. Regarding current trading prices, DXR is priced at $10.95, while WST trades at $304.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas WST's P/E ratio is 40.71. In terms of profitability, DXR's ROE is +0.22%, compared to WST's ROE of +0.18%. Regarding short-term risk, DXR is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check WST's competition here
DXR vs HOLX Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, DXR is priced at $10.95, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas HOLX's P/E ratio is 31.54. In terms of profitability, DXR's ROE is +0.22%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, DXR and HOLX have similar daily volatility (0.00).Check HOLX's competition here
DXR vs BDXB Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, DXR is priced at $10.95, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas BDXB's P/E ratio is 7.60. In terms of profitability, DXR's ROE is +0.22%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, DXR is less volatile compared to BDXB. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check BDXB's competition here
DXR vs COO Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, COO has a market cap of 11.9B. Regarding current trading prices, DXR is priced at $10.95, while COO trades at $60.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas COO's P/E ratio is 30.32. In terms of profitability, DXR's ROE is +0.22%, compared to COO's ROE of +0.05%. Regarding short-term risk, DXR is less volatile compared to COO. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check COO's competition here
DXR vs BAX Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, BAX has a market cap of 9.2B. Regarding current trading prices, DXR is priced at $10.95, while BAX trades at $17.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas BAX's P/E ratio is -9.32. In terms of profitability, DXR's ROE is +0.22%, compared to BAX's ROE of -0.16%. Regarding short-term risk, DXR is less volatile compared to BAX. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check BAX's competition here
DXR vs ATR Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, ATR has a market cap of 7.4B. Regarding current trading prices, DXR is priced at $10.95, while ATR trades at $115.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas ATR's P/E ratio is 19.82. In terms of profitability, DXR's ROE is +0.22%, compared to ATR's ROE of +0.14%. Regarding short-term risk, DXR is less volatile compared to ATR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ATR's competition here
DXR vs RGEN Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, RGEN has a market cap of 5.9B. Regarding current trading prices, DXR is priced at $10.95, while RGEN trades at $104.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas RGEN's P/E ratio is 114.51. In terms of profitability, DXR's ROE is +0.22%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, DXR is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check RGEN's competition here
DXR vs TFX Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, DXR is priced at $10.95, while TFX trades at $130.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas TFX's P/E ratio is 2175.33. In terms of profitability, DXR's ROE is +0.22%, compared to TFX's ROE of -0.28%. Regarding short-term risk, DXR is less volatile compared to TFX. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check TFX's competition here
DXR vs BLCO Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, BLCO has a market cap of 5.7B. Regarding current trading prices, DXR is priced at $10.95, while BLCO trades at $16.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas BLCO's P/E ratio is -25.98. In terms of profitability, DXR's ROE is +0.22%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, DXR is less volatile compared to BLCO. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check BLCO's competition here
DXR vs AVTR Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, AVTR has a market cap of 5.2B. Regarding current trading prices, DXR is priced at $10.95, while AVTR trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas AVTR's P/E ratio is -9.39. In terms of profitability, DXR's ROE is +0.22%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, DXR is less volatile compared to AVTR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check AVTR's competition here
DXR vs STVN Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, STVN has a market cap of 4.9B. Regarding current trading prices, DXR is priced at $10.95, while STVN trades at $17.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas STVN's P/E ratio is 29.62. In terms of profitability, DXR's ROE is +0.22%, compared to STVN's ROE of +0.10%. Regarding short-term risk, DXR is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check STVN's competition here
DXR vs MMSI Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, MMSI has a market cap of 3.8B. Regarding current trading prices, DXR is priced at $10.95, while MMSI trades at $63.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas MMSI's P/E ratio is 27.43. In terms of profitability, DXR's ROE is +0.22%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, DXR is less volatile compared to MMSI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check MMSI's competition here
DXR vs WRBY Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, WRBY has a market cap of 3.5B. Regarding current trading prices, DXR is priced at $10.95, while WRBY trades at $28.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas WRBY's P/E ratio is 2862.00. In terms of profitability, DXR's ROE is +0.22%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, DXR is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check WRBY's competition here
DXR vs ICUI Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, ICUI has a market cap of 3.1B. Regarding current trading prices, DXR is priced at $10.95, while ICUI trades at $123.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas ICUI's P/E ratio is 66.17. In terms of profitability, DXR's ROE is +0.22%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, DXR is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ICUI's competition here
DXR vs HAE Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, HAE has a market cap of 2.7B. Regarding current trading prices, DXR is priced at $10.95, while HAE trades at $57.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas HAE's P/E ratio is 15.79. In terms of profitability, DXR's ROE is +0.22%, compared to HAE's ROE of +0.11%. Regarding short-term risk, DXR is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check HAE's competition here
DXR vs LMAT Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, LMAT has a market cap of 2.3B. Regarding current trading prices, DXR is priced at $10.95, while LMAT trades at $100.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas LMAT's P/E ratio is 37.07. In terms of profitability, DXR's ROE is +0.22%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, DXR is less volatile compared to LMAT. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check LMAT's competition here
DXR vs NVCR Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, DXR is priced at $10.95, while NVCR trades at $17.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas NVCR's P/E ratio is -11.41. In terms of profitability, DXR's ROE is +0.22%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, DXR is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NVCR's competition here
DXR vs XRAY Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, XRAY has a market cap of 2B. Regarding current trading prices, DXR is priced at $10.95, while XRAY trades at $9.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas XRAY's P/E ratio is -3.12. In terms of profitability, DXR's ROE is +0.22%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, DXR is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check XRAY's competition here
DXR vs PLSE Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, PLSE has a market cap of 1.8B. Regarding current trading prices, DXR is priced at $10.95, while PLSE trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas PLSE's P/E ratio is -23.28. In terms of profitability, DXR's ROE is +0.22%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, DXR is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check PLSE's competition here
DXR vs STAA Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, STAA has a market cap of 1.6B. Regarding current trading prices, DXR is priced at $10.95, while STAA trades at $32.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas STAA's P/E ratio is -76.93. In terms of profitability, DXR's ROE is +0.22%, compared to STAA's ROE of -0.06%. Regarding short-term risk, DXR is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check STAA's competition here
DXR vs ATRC Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, ATRC has a market cap of 1.4B. Regarding current trading prices, DXR is priced at $10.95, while ATRC trades at $28.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas ATRC's P/E ratio is -284.80. In terms of profitability, DXR's ROE is +0.22%, compared to ATRC's ROE of -0.01%. Regarding short-term risk, DXR is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ATRC's competition here
DXR vs NNNN Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, NNNN has a market cap of 1.2B. Regarding current trading prices, DXR is priced at $10.95, while NNNN trades at $28.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas NNNN's P/E ratio is 187.67. In terms of profitability, DXR's ROE is +0.22%, compared to NNNN's ROE of +0.23%. Regarding short-term risk, DXR is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NNNN's competition here
DXR vs KMTS Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, KMTS has a market cap of 1.1B. Regarding current trading prices, DXR is priced at $10.95, while KMTS trades at $19.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas KMTS's P/E ratio is -3.59. In terms of profitability, DXR's ROE is +0.22%, compared to KMTS's ROE of -0.69%. Regarding short-term risk, DXR is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check KMTS's competition here
DXR vs BLFS Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, BLFS has a market cap of 1.1B. Regarding current trading prices, DXR is priced at $10.95, while BLFS trades at $22.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas BLFS's P/E ratio is -92.92. In terms of profitability, DXR's ROE is +0.22%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, DXR is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check BLFS's competition here
DXR vs ATRI Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, DXR is priced at $10.95, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas ATRI's P/E ratio is 64.50. In terms of profitability, DXR's ROE is +0.22%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, DXR is less volatile compared to ATRI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ATRI's competition here
DXR vs AZTA Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, AZTA has a market cap of 748.5M. Regarding current trading prices, DXR is priced at $10.95, while AZTA trades at $16.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas AZTA's P/E ratio is -6.74. In terms of profitability, DXR's ROE is +0.22%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, DXR is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check AZTA's competition here
DXR vs QDEL Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, QDEL has a market cap of 739.2M. Regarding current trading prices, DXR is priced at $10.95, while QDEL trades at $10.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas QDEL's P/E ratio is -0.61. In terms of profitability, DXR's ROE is +0.22%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, DXR is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check QDEL's competition here
DXR vs ANGO Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, ANGO has a market cap of 457.4M. Regarding current trading prices, DXR is priced at $10.95, while ANGO trades at $11.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas ANGO's P/E ratio is -14.57. In terms of profitability, DXR's ROE is +0.22%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, DXR is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ANGO's competition here
DXR vs OSUR Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, OSUR has a market cap of 207.2M. Regarding current trading prices, DXR is priced at $10.95, while OSUR trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas OSUR's P/E ratio is -2.87. In terms of profitability, DXR's ROE is +0.22%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, DXR is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check OSUR's competition here
DXR vs UTMD Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, UTMD has a market cap of 203.8M. Regarding current trading prices, DXR is priced at $10.95, while UTMD trades at $64.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas UTMD's P/E ratio is 18.93. In terms of profitability, DXR's ROE is +0.22%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, DXR is less volatile compared to UTMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check UTMD's competition here
DXR vs SMTI Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, SMTI has a market cap of 200.6M. Regarding current trading prices, DXR is priced at $10.95, while SMTI trades at $21.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas SMTI's P/E ratio is 364.83. In terms of profitability, DXR's ROE is +0.22%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, DXR is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check SMTI's competition here
DXR vs PDEX Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, PDEX has a market cap of 188.9M. Regarding current trading prices, DXR is priced at $10.95, while PDEX trades at $59.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas PDEX's P/E ratio is 16.30. In terms of profitability, DXR's ROE is +0.22%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, DXR is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check PDEX's competition here
DXR vs INFU Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, INFU has a market cap of 180.1M. Regarding current trading prices, DXR is priced at $10.95, while INFU trades at $8.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas INFU's P/E ratio is 24.12. In terms of profitability, DXR's ROE is +0.22%, compared to INFU's ROE of +0.14%. Regarding short-term risk, DXR is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check INFU's competition here
DXR vs KRMD Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, DXR is priced at $10.95, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas KRMD's P/E ratio is -76.60. In terms of profitability, DXR's ROE is +0.22%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, DXR is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check KRMD's competition here
DXR vs STXS Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, STXS has a market cap of 174.5M. Regarding current trading prices, DXR is priced at $10.95, while STXS trades at $1.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas STXS's P/E ratio is -7.44. In terms of profitability, DXR's ROE is +0.22%, compared to STXS's ROE of -1.53%. Regarding short-term risk, DXR is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check STXS's competition here
DXR vs NYXH Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, NYXH has a market cap of 109.4M. Regarding current trading prices, DXR is priced at $10.95, while NYXH trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas NYXH's P/E ratio is -1.17. In terms of profitability, DXR's ROE is +0.22%, compared to NYXH's ROE of -1.64%. Regarding short-term risk, DXR is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NYXH's competition here
DXR vs MBOT Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, MBOT has a market cap of 81.1M. Regarding current trading prices, DXR is priced at $10.95, while MBOT trades at $1.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas MBOT's P/E ratio is -6.85. In terms of profitability, DXR's ROE is +0.22%, compared to MBOT's ROE of -0.15%. Regarding short-term risk, DXR is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check MBOT's competition here
DXR vs ZTEK Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, ZTEK has a market cap of 79.6M. Regarding current trading prices, DXR is priced at $10.95, while ZTEK trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas ZTEK's P/E ratio is -12.33. In terms of profitability, DXR's ROE is +0.22%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, DXR is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ZTEK's competition here
DXR vs AKYA Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, DXR is priced at $10.95, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas AKYA's P/E ratio is -1.34. In terms of profitability, DXR's ROE is +0.22%, compared to AKYA's ROE of -27.96%. Regarding short-term risk, DXR and AKYA have similar daily volatility (0.00).Check AKYA's competition here
DXR vs OMIC Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, DXR is priced at $10.95, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas OMIC's P/E ratio is -0.58. In terms of profitability, DXR's ROE is +0.22%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, DXR is less volatile compared to OMIC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check OMIC's competition here
DXR vs IGAP Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, DXR is priced at $10.95, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas IGAP's P/E ratio is -10.52. In terms of profitability, DXR's ROE is +0.22%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, DXR is less volatile compared to IGAP. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check IGAP's competition here
DXR vs STSS Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, STSS has a market cap of 45.9M. Regarding current trading prices, DXR is priced at $10.95, while STSS trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas STSS's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to STSS's ROE of -1.66%. Regarding short-term risk, DXR is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check STSS's competition here
DXR vs NEPH Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, NEPH has a market cap of 40M. Regarding current trading prices, DXR is priced at $10.95, while NEPH trades at $3.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas NEPH's P/E ratio is 52.57. In terms of profitability, DXR's ROE is +0.22%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, DXR is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NEPH's competition here
DXR vs POCI Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, POCI has a market cap of 39.3M. Regarding current trading prices, DXR is priced at $10.95, while POCI trades at $5.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas POCI's P/E ratio is -7.94. In terms of profitability, DXR's ROE is +0.22%, compared to POCI's ROE of -0.37%. Regarding short-term risk, DXR is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check POCI's competition here
DXR vs SDC Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, DXR is priced at $10.95, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas SDC's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to SDC's ROE of -1.96%. Regarding short-term risk, DXR is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check SDC's competition here
DXR vs MLSS Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, MLSS has a market cap of 28.7M. Regarding current trading prices, DXR is priced at $10.95, while MLSS trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas MLSS's P/E ratio is -5.43. In terms of profitability, DXR's ROE is +0.22%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, DXR is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check MLSS's competition here
DXR vs EKSO Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, EKSO has a market cap of 28.6M. Regarding current trading prices, DXR is priced at $10.95, while EKSO trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas EKSO's P/E ratio is -2.31. In terms of profitability, DXR's ROE is +0.22%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, DXR is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check EKSO's competition here
DXR vs IVC Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, DXR is priced at $10.95, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas IVC's P/E ratio is -0.79. In terms of profitability, DXR's ROE is +0.22%, compared to IVC's ROE of -0.46%. Regarding short-term risk, DXR is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check IVC's competition here
DXR vs HBIO Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, HBIO has a market cap of 22.6M. Regarding current trading prices, DXR is priced at $10.95, while HBIO trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas HBIO's P/E ratio is -2.33. In terms of profitability, DXR's ROE is +0.22%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, DXR is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check HBIO's competition here
DXR vs RVP Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, RVP has a market cap of 20.5M. Regarding current trading prices, DXR is priced at $10.95, while RVP trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas RVP's P/E ratio is -1.59. In terms of profitability, DXR's ROE is +0.22%, compared to RVP's ROE of -0.08%. Regarding short-term risk, DXR is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check RVP's competition here
DXR vs ZJYL Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, ZJYL has a market cap of 19.1M. Regarding current trading prices, DXR is priced at $10.95, while ZJYL trades at $2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas ZJYL's P/E ratio is 12.20. In terms of profitability, DXR's ROE is +0.22%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, DXR is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ZJYL's competition here
DXR vs FEMY Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, FEMY has a market cap of 10.7M. Regarding current trading prices, DXR is priced at $10.95, while FEMY trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas FEMY's P/E ratio is -1.51. In terms of profitability, DXR's ROE is +0.22%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, DXR is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check FEMY's competition here
DXR vs RGNT Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, RGNT has a market cap of 7.6M. Regarding current trading prices, DXR is priced at $10.95, while RGNT trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas RGNT's P/E ratio is -0.08. In terms of profitability, DXR's ROE is +0.22%, compared to RGNT's ROE of N/A. Regarding short-term risk, DXR is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check RGNT's competition here
DXR vs NSTG Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, DXR is priced at $10.95, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas NSTG's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, DXR is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NSTG's competition here
DXR vs NXGL Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, NXGL has a market cap of 4.7M. Regarding current trading prices, DXR is priced at $10.95, while NXGL trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas NXGL's P/E ratio is -1.28. In terms of profitability, DXR's ROE is +0.22%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, DXR is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NXGL's competition here
DXR vs NXGLW Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, NXGLW has a market cap of 4.3M. Regarding current trading prices, DXR is priced at $10.95, while NXGLW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas NXGLW's P/E ratio is -0.04. In terms of profitability, DXR's ROE is +0.22%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, DXR and NXGLW have similar daily volatility (0.00).Check NXGLW's competition here
DXR vs LUCY Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, LUCY has a market cap of 3.8M. Regarding current trading prices, DXR is priced at $10.95, while LUCY trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas LUCY's P/E ratio is -0.49. In terms of profitability, DXR's ROE is +0.22%, compared to LUCY's ROE of -0.00%. Regarding short-term risk, DXR is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check LUCY's competition here
DXR vs POAI Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, DXR is priced at $10.95, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas POAI's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to POAI's ROE of -107.05%. Regarding short-term risk, DXR is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check POAI's competition here
DXR vs MHUA Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, DXR is priced at $10.95, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas MHUA's P/E ratio is 0.25. In terms of profitability, DXR's ROE is +0.22%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, DXR and MHUA have similar daily volatility (0.00).Check MHUA's competition here
DXR vs GMVD Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $10.95, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas GMVD's P/E ratio is -0.01. In terms of profitability, DXR's ROE is +0.22%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GMVD's competition here
DXR vs GMVDW Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $10.95, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas GMVDW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GMVDW's competition here
DXR vs AVGR Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, DXR is priced at $10.95, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas AVGR's P/E ratio is -0.05. In terms of profitability, DXR's ROE is +0.22%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, DXR is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check AVGR's competition here
DXR vs STSSW Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, STSSW has a market cap of 867.5K. Regarding current trading prices, DXR is priced at $10.95, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas STSSW's P/E ratio is -0.04. In terms of profitability, DXR's ROE is +0.22%, compared to STSSW's ROE of -1.66%. Regarding short-term risk, DXR is less volatile compared to STSSW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check STSSW's competition here
DXR vs LUCYW Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, DXR is priced at $10.95, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas LUCYW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to LUCYW's ROE of -0.00%. Regarding short-term risk, DXR is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check LUCYW's competition here
DXR vs GCTK Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, GCTK has a market cap of 274.1K. Regarding current trading prices, DXR is priced at $10.95, while GCTK trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas GCTK's P/E ratio is -0.02. In terms of profitability, DXR's ROE is +0.22%, compared to GCTK's ROE of -2.83%. Regarding short-term risk, DXR is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GCTK's competition here
DXR vs WOK Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, WOK has a market cap of 2.2K. Regarding current trading prices, DXR is priced at $10.95, while WOK trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas WOK's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to WOK's ROE of -0.07%. Regarding short-term risk, DXR is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check WOK's competition here
DXR vs APR Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, APR has a market cap of 0. Regarding current trading prices, DXR is priced at $10.95, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas APR's P/E ratio is 22.59. In terms of profitability, DXR's ROE is +0.22%, compared to APR's ROE of +9.81%. Regarding short-term risk, DXR is less volatile compared to APR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check APR's competition here
DXR vs ARTC Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, ARTC has a market cap of 0. Regarding current trading prices, DXR is priced at $10.95, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas ARTC's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to ARTC's ROE of N/A. Regarding short-term risk, DXR and ARTC have similar daily volatility (0.00).Check ARTC's competition here
DXR vs IIN Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, IIN has a market cap of 0. Regarding current trading prices, DXR is priced at $10.95, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas IIN's P/E ratio is 226.45. In terms of profitability, DXR's ROE is +0.22%, compared to IIN's ROE of -0.00%. Regarding short-term risk, DXR is less volatile compared to IIN. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check IIN's competition here
DXR vs ALOG Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, DXR is priced at $10.95, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas ALOG's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, DXR and ALOG have similar daily volatility (0.00).Check ALOG's competition here
DXR vs IVTY Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, DXR is priced at $10.95, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas IVTY's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, DXR and IVTY have similar daily volatility (0.00).Check IVTY's competition here
DXR vs ATRS Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, DXR is priced at $10.95, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas ATRS's P/E ratio is 14.95. In terms of profitability, DXR's ROE is +0.22%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, DXR is less volatile compared to ATRS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ATRS's competition here
DXR vs HRC Comparison May 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 54.5M. In comparison, HRC has a market cap of 0. Regarding current trading prices, DXR is priced at $10.95, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.59, whereas HRC's P/E ratio is 41.92. In terms of profitability, DXR's ROE is +0.22%, compared to HRC's ROE of +0.14%. Regarding short-term risk, DXR is less volatile compared to HRC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check HRC's competition here